Jenburkt Pharmaceuticals Past Earnings Performance
Past criteria checks 4/6
Jenburkt Pharmaceuticals has been growing earnings at an average annual rate of 8.8%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 3.2% per year. Jenburkt Pharmaceuticals's return on equity is 18.7%, and it has net margins of 17.7%.
Key information
8.8%
Earnings growth rate
10.0%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 3.2% |
Return on equity | 18.7% |
Net Margin | 17.7% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Jenburkt Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1,383 | 244 | 412 | 0 |
30 Sep 23 | 1,372 | 245 | 401 | 0 |
30 Jun 23 | 1,348 | 240 | 393 | 0 |
31 Mar 23 | 1,367 | 246 | 388 | 0 |
31 Dec 22 | 1,298 | 217 | 388 | 0 |
30 Sep 22 | 1,283 | 225 | 380 | 0 |
30 Jun 22 | 1,279 | 236 | 370 | 0 |
31 Mar 22 | 1,240 | 223 | 365 | 0 |
31 Dec 21 | 1,252 | 227 | 353 | 0 |
30 Sep 21 | 1,241 | 224 | 341 | 0 |
30 Jun 21 | 1,190 | 201 | 329 | 0 |
31 Mar 21 | 1,093 | 165 | 324 | 0 |
31 Dec 20 | 1,100 | 172 | 340 | 0 |
30 Sep 20 | 1,118 | 159 | 346 | 0 |
30 Jun 20 | 1,155 | 158 | 358 | 0 |
31 Mar 20 | 1,189 | 149 | 365 | 0 |
31 Dec 19 | 1,237 | 171 | 352 | 0 |
30 Sep 19 | 1,224 | 170 | 341 | 0 |
30 Jun 19 | 1,202 | 172 | 322 | 0 |
31 Mar 19 | 1,226 | 198 | 312 | 0 |
31 Dec 18 | 1,176 | 185 | 299 | 0 |
30 Sep 18 | 1,162 | 186 | 290 | 0 |
30 Jun 18 | 1,209 | 228 | 290 | 0 |
31 Mar 18 | 1,147 | 172 | 279 | 0 |
31 Dec 17 | 1,120 | 151 | 277 | 0 |
30 Sep 17 | 1,060 | 136 | 273 | 0 |
30 Jun 17 | 980 | 86 | 259 | 0 |
31 Mar 17 | 1,033 | 135 | 252 | 0 |
31 Dec 16 | 979 | 112 | 263 | 0 |
30 Sep 16 | 972 | 118 | 252 | 0 |
30 Jun 16 | 937 | 102 | 247 | 0 |
31 Mar 16 | 936 | 108 | 241 | 0 |
31 Dec 15 | 940 | 117 | 432 | 7 |
30 Sep 15 | 911 | 109 | 427 | 7 |
30 Jun 15 | 882 | 107 | 196 | 0 |
31 Mar 15 | 852 | 96 | 203 | 0 |
31 Dec 14 | 827 | 97 | 383 | 6 |
30 Sep 14 | 809 | 90 | 377 | 6 |
30 Jun 14 | 784 | 81 | 175 | 0 |
31 Mar 14 | 762 | 75 | 371 | 6 |
31 Dec 13 | 735 | 69 | 172 | 0 |
30 Sep 13 | 717 | 64 | 171 | 0 |
30 Jun 13 | 716 | 63 | 163 | 0 |
Quality Earnings: 524731 has high quality earnings.
Growing Profit Margin: 524731's current net profit margins (17.7%) are higher than last year (16.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524731's earnings have grown by 8.8% per year over the past 5 years.
Accelerating Growth: 524731's earnings growth over the past year (12.7%) exceeds its 5-year average (8.8% per year).
Earnings vs Industry: 524731 earnings growth over the past year (12.7%) did not outperform the Pharmaceuticals industry 23.1%.
Return on Equity
High ROE: 524731's Return on Equity (18.7%) is considered low.